Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2026)
Genmab A's (GMAB) quarterly Non-Current Deffered Revenue came in at $95.0 million in Q4 2025, up 41.79% YoY from $67.0 million in Q4 2024, and up 41.79% on a QoQ basis from $67.0 million in Q2 2025.
Genmab A (GMAB) Non-Current Deffered Revenue (2023 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Non-Current Deffered Revenue data on file, last reported at $95.0 million in Q4 2025.
- Quarterly Non-Current Deffered Revenue rose 41.79% year-over-year to $95.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $95.0 million (up 41.79% YoY) and the FY2025 annual result came in at $95.0 million, up 41.79% from the prior year.
- Non-Current Deffered Revenue advanced to $95.0 million in Q4 2025, from $67.0 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $95.0 million in Q4 2025 to a low of $67.0 million in Q4 2024.
- A 3-year average of $75.0 million and a median of $69.0 million in 2023 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue retreated 5.63% — and 2025, when it surged 41.79%.
- Tracing GMAB's Non-Current Deffered Revenue over 3 years: stood at $71.0 million in 2023, then slipped by 5.63% to $67.0 million in 2024, then soared by 41.79% to $95.0 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $95.0 million (Q4 2025), $67.0 million (Q2 2025), and $67.0 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 88.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 88.00 Mn |
| Dec 31, 2025 | 95.00 Mn |
| Jun 30, 2025 | 67.00 Mn |
| Dec 31, 2024 | 67.00 Mn |
| Dec 31, 2023 | 71.00 Mn |